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Identity 
Other names: ACTRI, ACVR1A, ACVRLK2, ALK2, 
FOP, SKR1, TSRI 
HGNC (Hugo): ACVR1 
Location: 2q24.1 
Local order: According to UCSC Genome Browser on 
Human Feb. 2009 (GRCh37/hg19) Assembly, genes 
flanking ACVR1 in centromere to telomere direction 
on 2q24.1 are: 
- PKP4 (plakophilin-4 isoform b), 
- CCDC148 (coiled-coil domain-containing protein 148 
isoform 1), 
- UPP2 (uridine phosphorylase 2 isoform a), 
- ACVR1 (activin A receptor, type I), 
- ACVR1C (activin A receptor, type IC (ACVR1C), 
- CYTIP (cytohesin 1 interacting protein), 
- ERMN (ermin, ERM-like protein), 
- and GALNT5 (UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 5 (GalNAc-T5). 
DNA/RNA 
Description 
The human ACVR1 gene contains 11 verified exons 
and spans 139417 bp on chromosome 2q24.1, 
nucleotide position from 158592958 to 158732374. 
Transcription 
The two curated transcripts from ACVR1, mRNA 
variants 1 and 2, encode the same protein. 
Associated RNA sequences are listed as follow:  
uc002tzn.3 and uc010fog.2 (UCSC genes); 
NM_001105.4 and NM_001111067.2 (RefSeq); 
OTTHUMT00000254927, OTTHUMT00000332969 
and OTTHUMT00000402326 (Vega); 
ENST00000263640, ENST00000409283, 
ENST00000410057, and ENST00000434821 
(Ensembl) and BC033867 (MGC). 
Protein 
Note 
Consensus coding sequence (CDS) unique identifier 
number: 2206.1_prot. 
Protein associated sequences: NP_001096.1 and 




ENSP00000387127, and ENSP00000405004 
(Ensembl). 
Description 
The ACVR1 gene encodes a transmembrane protein 
which is a member of bone morphogenetic protein 
(BMP) type I receptors included in the TGF-B 
receptors subfamily.  
The protein contains 509 amino acids residues and 
comprises a single transmembrane and three conserved 
domains, including: 
- Activin-recp domain: a specific hydrophilic Cys-rich 
ligand-binding domain characterized by 9 amino acid 
cysteine box, with the consensus CCX{4-5}CN and 7 
extracellular residues preceding the cysteine box. 
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Physical mapping of ACVR1 gene on chromosome 2q24.1. The two curated transcript variants (NM_001105.4 and NM_001111067.2) 
of ACVR1 encode the same protein of 509 amino acids containing a single transmembrane and three conserved domains (cyan - Activin 
receptor, blue - TGF-beta and red - Pkinase domains). (UCSC Genome Browser on Human, assembly GRCh37/hg19). 
 
- TGT_beta_GS domain: the GS motif is characterized 
by the highly conserved GSGSGLP signature in the 
cytoplasmic juxtamembrane region immediately 
preceding the protein's kinase domain. This motif is 
found in the transforming growth factor beta (TGF-
beta) type I which regulates cell growth and 
differentiation. 
- Catalytic domain of Protein Kinases: this domain 
catalyzes the transfer of the gamma-phosphoryl group 
from ATP to serine/threonine on protein substrates.  
Protein kinases regulate many cellular processes 
including proliferation, division, differentiation, 
motility, survival, metabolism, cell-cycle progression, 
cytoskeletal rearrangement, immunity, and neuronal 
functions. 
Expression 
This gene is ubiquitously expressed in normal 
parenchymal cells, endothelial cells, fibroblasts and 
tumor-derived epithelial cells 
(http://www.informatics.jax.org/marker/MGI:87911). 
By using a polymerase chain reaction (PCR)-based 
strategy, Dijke et al. (1993) characterized cDNA clones 
encoding four putative transmembrane protein 
serine/threonine kinases, named as activin receptor-like 
kinases (ALK) -1, -2, -3 and -4. The ALKs have 
approximately 40% sequence identity to activin 
receptor type II and activin receptor type IIB, 
transforming growth factor-beta (TGF-beta) type II 
receptor and Daf-1 in the kinase domains. Since the 
sequence identities were higher (60-79%) between 
ALK-1, -2, -3 and -4, the authors suggested that they 
form a subfamily among the putative receptor 
serine/threonine kinases.  
Further, in this study it was observed that the 
expression of mRNA in human tissues varied for the 
different ALKs; ALK-2 (nowadays, ACVR1) and 
ALK-4 showed ubiquitous tissue expression patterns, 
whereas the distribution of other members, such as 
ALK-1 and ALK-3, varied strongly between different 
tissues with more restricted expression patterns. 
Localisation 
ACVR1 is a single-pass type I membrane protein. 
Function 
Activins are dimeric factors belonging to the 
transforming growth factor-b (TGF-beta) family, whic  
also includes the TGF-beta and the bone 
morphogenetic proteins (BMPs) (Attisano et al., 1996). 
At first, the ACVR1 was identified as an activin type I 
receptor for its ability to bind activin in concert with 
ActRII or ActRIIB. ACVR 1 is also identified as a 
BMP type I receptor, and has demonstrated its ability to 
form a complex with either the BMP-2/7-bound 
BMPR-II or ACVR2A/ACVR2B (Liu et al., 2002). 
The activin A type I receptor is essential for activin 
signaling, while type II receptors are required for 
binding ligands.  
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TGFβ signaling. TGFβ signaling involves a heteromeric complex involving type II (RII) and type I (RI) serine/threonine kinase receptors, 
resulting in the activation of type I receptor (red). Once activated, type I receptor subsequently phosphorylates the intracellular proteins of 
at least two interacting signaling cascades: the canonical Smad pathway and the p38 mitogen-activated protein kinase (p38 MAPK) 
pathway. The networks were generated through the use of IPA (Ingenuity Systems). 
 
On ligand binding, forms a stable complex, resulting i  
phosphorylation of type I receptors by type II receptors. 
Once phosphorylated, the complex activates 
intracellular signaling mediated by the Smad proteins 
and several non-Smad signaling pathways. Smads 
interact with Smad4 and translocate to the nucleus 
where they regulate gene expression (see diagram). 
Homology 
ACVR1 belongs to the protein kinase superfamily, 
TKL Ser/Thr protein kinase family, TGFB receptor 
subfamily. These receptors are composed of a ligand-
binding extracellular domain with cysteine-rich region, 
a transmembrane domain, and a cytoplasmic domain 
with predicted serine/threonine specificity 
(HomoloGene). 
The ACVR1 gene is conserved in chimpanzee, rhesus 
monkey, dog, cow, mouse, rat, chicken, zebrafish, fruit
fly, and mosquito. 
Mutations 
Note 
Human ACVR1 was indicated as a candidate gene to 
Fibrodysplasia Ossificans Progressiva (FOP) by Shore  
 
et al. (2006). This condition is an autosomal dominant 
disorder of connective tissue characterized by 
congenital malformations of the great toes and 
progressive heterotopic ossification of muscles, tendon, 
ligament, and fascia. In this first study (Shore et al., 
2006), the FOP phenotype was linked to markers 
located in the 2q23-q24 interval; interestingly, an
identical heterozygous mutation (617G>A; R206H) in 
the glycine-serine (GS) activation domain of ACVR1 
gene was detected in all affected individuals examined. 
Germinal 
DNA sequencing of all ACVR1 protein-coding exons 
and splice junctions identified a heterozygous mutation 
(the transition 617G>A; R206H) in affected members 
of five families evaluated by linkage analysis, and i  32 
out of 32 sporadic FOP patients with classical clini al 
features (Shore et al., 2006). Recurrent associations 
betweem R206H mutation and FOP were subsequently 
confirmed in unrelated sporadic FOP patients (Lin et 
al., 2006; Nakajima et al., 2007; Bocciardi et al.,2009; 
Kaplan et al., 2009; Lee et al., 2009; Sun et al., 2009; 
Carvalho et al., 2010; Du et al., 2010; Guo et al., 2010; 
Dandara et al., 2012; Eresen Yazicioglu et al., 2013 ; 
Morales-Piga et al., 2012).  
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Additional ACVR1 missense mutations were described 
in atypical FOP patients. These patients were defined 
based on the classic features of FOP plus one or more
atypical features (FOP plus) and included patients 
showing variations in one or both of the two classic 
clinical signs of FOP. The new mutations detected wre 
transitions 587T>C(L196P) (Gregson et al., 2011; Ohte 
et al., 2011), 982G>A(G328R) (Kaplan et al., 2009), 
983G>A(G328E) (Kaplan et al., 2009; Petrie et al., 
2009), 1097G>A(G356D) (Fukuda et al., 2008; Furuya 
et al., 2008; Kaplan et al., 2009) as well transverions 
605G>T(R201I) (Pietrie et al., 2009; Barnett et al., 
2011), 774G>C(R258S) (Bocciardi et al., 2009; 
Morales-Piga et al., 2012), 774G>T(R258S) (Rabti et 
al., 2010; Morales-Piga et al. 2012; Eresen Yazicioglu 
et al., 2013), 974G>C(G325A) (Whyte at al., 2012) and
1124G>C(R375P) (Kaplan et al., 2009).  
Protein structure homology modeling predicts that each 
of the amino acid substitutions of the TGF-beta-GS 
motif or the kinase domain of the activin A receptor I 
in FOP patients are gain-of-function mutations that 
activates the ACVR1 protein to enhance receptor 
signaling pathway (Kaplan et al., 2009). 
Somatic 
Somatic mutations of ACVR1 gene were described in 
primary ovary and colon cancer as well as in melanoma 
cell line (Font: COSMIC Project - Catalogue of 
Somatic Mutations in Cancer, online data available in 
COSMIC). 
Implicated in 
Head and neck cancer 
Note 
The ACVR1 gene is mapped in a region frequently 
related in gains detected by chromosomal CGH and 
array-CGH analysis in several cancer types. Ambrosio 
et al. (2011) reported that copy number alterations f 
2q24.1 were associated with ACVR1 overexpression 
and with longer overall survival in laryngeal 
carcinomas. 
Prognosis 
In the study of Ambrosio et al. (2011), it was described 
at first that oral cavity, laryngeal and pharyngeal 
carcinomas presented ACVR1 overexpression in 
agreement with 2q24 gains and amplifications detectd 
by FISH analysis.  
No statistical association was observed between its 
expression and clinicopathological parameters; 
however, when laryngeal carcinomas were considered 
separately, multivariate analysis revealed that ACVR1 
overexpression was associated with longer overall 
survival, suggesting that this gene is a putative 
prognostic marker in laryngeal squamous cell 
carcinoma. 
 
Illustrative scheme showing an intragenic region of ACVR1 copy number gains in oropharyngeal carcinoma after array-
Comparative Genomic Hybrydization (aCGH) analysis. The gain region comprises a 30Kb segment of ACVR1 gene covered by three 
consecutive probes (blue dots) (personal communication). 
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Cytogenetics 
Twenty-eight samples of squamous cell carcinoma 
were evaluated by fluorescence in situ hybridization 
(FISH) using the probes RP11- 546J1 (2q24) and 
RP11-21P18 (internal control).  
Significant gains at 2q24 were detected in most cases t 




In prostate cancer cell lines (Pca cells), it has been 
proposed that endoglin abrogates TGFβ-mediated 
increases in cell motility.  
Craft et al. (2008) demonstrated that both Smad1 and 
ACVR1/ALK2 are necessary for endoglin-mediated 
suppression of cell motility and that constitutively 
active ACVR1/ALK2 was sufficient to restore a low-
motility phenotype in endoglin deficient cells.  
Futher, by using RT-qPCR, it was detected that 
ACVR1/ALK2 was expressed at high levels in PCa 
cells, and was increased four fold compared to ALK5 
expression in both PC3 and PC3-M cells. 
Subsequently, Romero et al. (2010) provided new 
evidences for a novel Smad-independent TGF-β 
effector that regulates cell migration via 
phosphorylation of endoglin by ACVR1. 
According to the authors, upon TGF-β1 stimulation, 
ALK5 phosphorylates Smad2 and Smad3 with a 
negative impact on ACVR1/ALK2-Smad1, Smad5 and 
Smad8 signaling.  
Thus, ACVR1/ALK2 phosphorylates endoglin as an 
alternative substrate; while after BMP7 stimulation, 
ACVR1/ALK2 phosphorylates endoglin without a 
requirement for ALK5 participation. 
Colon cancer 
Note 
It has been suggested that Activin receptor 2 (ACVR2) 
is commonly mutated in microsatellite unstable (MSI) 
colon cancers, leading to protein loss, signaling 
disruption, and to a larger tumors. Thus, Jung et al. 
(2009) examined activin signaling disruption of three 
components of this pathway in microsatellite stable 
(MSS) colon cancers, including ACVR1, ACVR2 and 
pSMAD2 protein expression analysis and loss of 
heterozigosity assays.  
Only a small percentage of MSS colon cancers lost 
expression of activin signaling members: of a total f 
51 tumors analysed, only 2 samples (4%) lost ACVR1 
expression. The authors suggested that, loss of ACVR2, 
ACVR1 and pSMAD2 expression may occur in a 
subset of MSS tumors, possibly indicating the 
abrogation of the normal growth suppressive activity of 
activin signaling. Furthermore, the authors suggested 
that activin signaling could be inactivated by distinc ive 




Herrera et al. (2009) demonstrated that BMP9 acts as a 
proliferative factor for immortalized ovarian surface 
epithelial cells and ovarian cancer cell lines, signaling 
predominantly through an ACVR1/Smad1/Smad4 
pathway rather than through ALK1, the major BMP9 
receptor in endothelial cells. In addition, it was 
observed that ovarian cancer cell lines gained autocrine 
BMP9 signaling and that 25% of epithelial ovarian 
cancers express BMP9, whereas normal human ovarian 
surface epithelial specimens do not. These data indicate 
that BMP9 signaling through ACVR1 may be a novel 
therapeutic target in ovarian cancer. 
Breast cancer 
Note 
Bone morphogenetic proteins (BMP) are thought to be 
associated with breast cancer promotion and 
progression. Takahashi et al. (2008) reported that 
activin decreased ESR1 mRNA expression, while 
BMP6 and BMP7 impaired steroid sulfatase expression 
in MCF-7 cells. It was suggested that the difference of 
BMP responsiveness could be related to the fact that 
estradiol decreased the expression levels of BMPR1A, 
BMPR1B, ACVR2A, and ACVR2B but did not affect 
ACVR1 and BMPRII. Thus, estradiol rapidly could 
activate MAPK phosphorylation including extracellular 
signal-regulated kinase 1/2, p38, and stress-activated 
protein kinase/c-Jun NH2-terminal kinase pathways 
and BMP6, BMP7, but activin could preferentially 
inhibit estradiol-induced p38 phosphorylation. In this 
study, it was also demonstrated that SB203580 (a 
selective p38 MAPK inhibitor) effectively suppressed 
estradiol-induced cell mitosis, suggesting that p38 
MAPK plays a key role in estrogen-sensitive breast 
cancer cell proliferation. The authors suggested that t e 
inhibitory effects of BMP6 and BMP7 on p38 signaling 
and steroid sulfatase expression could lead to the 
suppression of estrogen-induced mitosis of breast 
cancer cells. 
Recently, Slattery et al. (2012) evaluated the possible 
association between genetic variation in BMP-related 
genes and the risk of breast cancer development among 
Hispanic (2111 cases, 2597 controls) and non-Hispanc 
White (NHW) (1481 cases, 1586 controls) women. 
Interestingly, after adjustment for multiple 
comparisons, specific SNPs of ACVR1 gene was 
modestly associated with breast cancer risk according 
to the ER and PR status of the tumors.  
Eigth out of 16 single nucleotide polymorphisms 
(SNPs) of the ACVR1 gene were associated with 
ER+PR+ tumors, although the level of association was
modest with ORs between 1.19 and 1.33. Further, fou 
and one ACVR1 SNPs were associated with ER+PR- 
and ER-PR- tumors, respectively. The rare A-T 
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haplotype of rs4380178 and rs17182166 of this gene  
was associated with an OR of 1.51 (95% CI 1.14, 2.00). 
The polymorphisms ACVR1 rs1220134 and ACVR2A 
rs10497025 were associated with reduced breast cancer 
risk. However, for the ACVR1 rs17182166 
polymorphism, the association was stronger with ER- 
as well ER-PR- tumors. 
Polycystic ovary syndrome 
Note 
Polycystic ovary syndrome (PCOS) is an 
endocrinological condition associated with infertility 
and metabolic abnormalities. Considering that members 
of the transforming growth factor beta family, anti-
Müllerian hormone (AMH) and bone morphogenetic 
proteins (BMPs) inhibit FSH sensitivity, it has been 
proposed that TGF-beta signalling may contribute to 
the aberrant follicle development in women with 
PCOS. Kevenaar et al. (2009) evaluated seven ACVR1 
single nucleotide polymorphisms in 359 PCOS patients 
and 30 normo-ovulatory as well as in 3543 population-
based control women. Although the polymorphisms 
rs1220134, rs10497189 and rs2033962 and their 
corresponding haplotypes did not differ between cases 
and controls, it was detected and associated with AMH 
levels in PCOS women. The authors suggested that 
genetic variants of ACVR1 may be associated with 
AMH levels and follicle number in PCOS women, 
contributing to abnormal folliculogenesis in PCOS 
patients. 
To be noted 
Note 
ACVR1 as therapeuthic target in FOP patients. 
Although the regulation of ACVR1/Alk-2 gene 
expression is still poorly understood, it was well 
establisehd that ACVR1 mutations in FOP patients 
result in constitutive activation of the receptor (Shore 
and Kaplan, 2011). This is of importance, since 
inhibition of aberrant ACVR1 signaling represents an 
attractive therapeutic approach for these patients. 
Kaplan et al. (2011) and Takahashi et al. (2012) were 
able to selectively suppress the effect of mutations f 
ACVR1 using an allele-specific RNA interference 
(ASP-RNAi) approach to target the mutated ACVR1 
mRNA for degradation. 
MicroRNAs (miRNAs) also play an essential role in 
regulating cell differentiation. Recently, it was reported 
that specific miRNAs are involved in modulating 
ACVR1/Alk-2 gene expression as suggested by binding 
sites prediction, reporter gene assays and mutational 
analysis at the miRNA binding sites. These studies 
have indicated that mir148b and mir365 were able to 
down-regulate ACVR1/Alk-2 expression, whereas 
mir26a showed a positive effect on its mRNA (Mura et 
al., 2012; Song et al., 2012). These findings suggest 
that miR-148a is an important mediator of ACVR1, 
thus offering a new potential target for the development 
of therapeutic agents against FOP. 
Animal Model. Chakkalakal et al. (2012) developed a 
gene targeting strategy to obtain an Acvr1 knock-in 
model for FOP (Acvr1(R206H/+)). This unique knock-
in mouse model provided novel insight into the genetic 
regulation of heterotopic ossification and established 
the first direct in vivo evidence that the R206H 
mutation of ACVR1 causes FOP. The authors 
demonstrated that the phenotype of Acvr1(R206H/ ) 
chimeric mice resemble the human disease: after 
radiographic analysis, it was observed that this 
mutation induced malformed first digits in the hind 
limbs and postnatal extraskeletal bone formation. 
Histological analysis of murine lesions showed 
inflammatory infiltration and apoptosis of skeletal 
muscle associated with formation of heterotopic bone 
through an endochondral pathway, as seen in FOP 
patients. 
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